| CCY | SZE(M) | TNR | MTY | RNK | MO | SP | FI | TYPE | BNCH | IPT | GDNC | SPRD | CPN | NIC | PRICE |
|---|
| EUR | 590.000 | 5 | Nov-24 | Sr. Unsecured | A3 | A- | - | Fixed | Swaps | MS+60-65 | MS+40-45 | 40 | 0.10% | - | 99.64200 |
| EUR | 590.000 | 8 | Nov-27 | Sr. Unsecured | A3 | A- | - | Fixed | Swaps | MS+80 a | MS+55 a | 52 | 0.38% | -4 | 99.25600 |
Tranche Comments
5 yr: Book size: 1400; Registration: Reg S Only; Comments: EUR590m 5yr. With 8yr. RegS. A3/A-. Barc(B&D)/BofA/JPM/MS. IPTs MS+60/+65, guidance MS+40/45, set MS+40, bk ~1.4bn (peaked ~2.1bn), HR 98% vs OBL Oct 2024+75.6 @102.92. 1mPC. B+15 MWC. FTT 3.45pm. Tax Call: No. PP: No. XD: No;
8 yr: Book size: 1500; Registration: Reg S Only; Comments: EUR590m 8yr. With 5yr. RegS. A3/A-. Barc(B&D)/BofA/JPM/MS. IPTs MS+80 area, guidance MS+55 (+/-3), set MS+52, bk ~1.5bn (peaked ~3.25bn). HR 95% vs DBR Aug 2027+95 @107.75. MWC B+20, 3mPC. FTT 3.45pm. Tax Call: No. PP: No. XD: No;
Guarantor(s)
Abbott Laboratories
Use of Proceeds
Refinancing